Stonking Small Caps: shares soar on FDA approval
The enhanced medical imaging delivered by this company’s brilliant technology appears to have considerable potential in a huge market and it is yet another company where COVID-19 has accelerated interest. Long-awaited FDA approval for its drug-device combination product has seen the shares soar, it's now down to effective commercialisation.
A news release on 25 May 2021 concerning a study carried out in longer-term lung damage after COVID-19 determined that specialised scans had found abnormalities in the lungs of some COVID-19 patients more than three months - and in some cases, nine months - after leaving hospital, when other clinical measurements were normal.
Principal Investigator Prof Fergus Gleeson, Professor of Radiology at the University of Oxford, said:
"Many COVID-19 patients are still experiencing…
Continue reading our content…
- Unlimited access to our market-beating portfolios
- In-depth coverage of many of the world’s great companies
- Unique insights from our top research team
- Company and markets insights
- Sponsored content
Previous article Next article